Received Oct 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | JB4K2 | — |
Inadvertent administration of a pediatric dose to an adult patient; Underdose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 26-year-old female patient who received HBV (Engerix B pediatric) (batch number JB4K2, expiry date 23-JAN-2027) for prophylaxis. On 19-SEP-2025, the patient received Engerix B pediatric. On 19-SEP-2025, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: Inadvertent administration of a pediatric dose to an adult patient) and underdose (Verbatim: Underdose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-SEP-2025 Licensed practical nurse calls to report the inadvertent administration of a pediatric dose to an adult patient and to request further guidance on this topic. The reporter consented to follow up.